Advertisement
Screener

Exelixis Inc (EXEL) Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss

3.5 / 5 stars · 77/111 Roast Me

Exelixis Inc Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss

Exelixis Inc (EXEL) had Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss of $71.00 thousand as of 2016-09-30, per its 10-Q filed 2016-11-03.

Discontinued › Notes › Investments

us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss · last filed 2016-11-03

  • 2016-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $71.00K.
  • 2016-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $11.00K.
  • 2016-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $18.00K.
  • 2015-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $13.00K.
Period endAvailable-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss
2016-09-30$71.00K
10-Q · filed 2016-11-03
2016-06-30$11.00K
10-Q · filed 2016-08-03
2016-03-31$18.00K
10-Q · filed 2016-05-04
2015-09-30$13.00K
10-Q · filed 2015-11-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Twist Bioscience Corp (TWST)United States$11.540B-47.21
BIO-TECHNE Corp (TECH)United States$11.379B74.68
REPLIGEN CORP (RGEN)United States$10.755B185.31
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
Immunovant, Inc. (IMVT)United States$7.028B-14.78